Metraipolis › archive › dc_7fc6370d46a1

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene… — Europe PMC PMID:41132654

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41132654
DOI
10.3389/fimmu.2025.1667249
License (as archived)
solo-consultazione
Archived
2026-11-09T12:22:18.078Z
SHA-256 of the archived text
ca751143dc80dc9fda441e746fb9d29c687e4e70dc716d3fefdcaf9dde88d694
Stable URL of this page
https://metraipolis.com/documento/dc_7fc6370d46a1

How to cite

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene… — Europe PMC PMID:41132654 — Europe PMC (en), https://europepmc.org/article/MED/41132654 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7fc6370d46a1 (Metraipolis archive dc_7fc6370d46a1, sha256 ca751143dc80dc9fda441e746fb9d29c687e4e70dc716d3fefdcaf9dde88d694)
BibTeX
@misc{dc7fc6370d46a1,
  title = {Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene… — Europe PMC PMID:41132654},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41132654},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7fc6370d46a1; sha256 ca751143dc80dc9fda441e746fb9d29c687e4e70dc716d3fefdcaf9dde88d694},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41132654. Agents can read the archived copy with the MCP tool read_document.